Crizotinib hydrochloride (PF-02341066 hydrochloride) |

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
10 mg	3-5days	￥600.00	Visible after login	- +
25 mg	3-5days	￥980.00	Visible after login	- +
50 mg	3-5days	￥1568.00	Visible after login	- +

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

10 mg

3-5days

￥600.00

Visible after login

- +

25 mg

3-5days

￥980.00

Visible after login

- +

50 mg

3-5days

￥1568.00

Visible after login

- +

Product Overview

Product Name	Crizotinib hydrochloride \| PF-02341066 hydrochloride
CAS	1415560-69-8
Formula	C21H23Cl3FN5O
MW	486.80
Appearance	Yellow to brown powder
Storage condition	4°C, sealed storage, away from moisture

Product details

Crizotinib HCl (formerly known as PF-02341066 hydrochloride; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK, with IC50 values of 11 nM and 24 nM in assays involving cells, respectively. In the US, crizotinib is licensed for the treatment of non-small cell lung cancer (NSCLC). It is also being investigated in clinical trials for safety and effectiveness in the treatment of neuroblastoma, anaplastic large cell lymphoma, and other advanced solid tumors in both adults and children. Crizotinib inhibits the activation of the MET signaling pathway and the membrane receptor MET, which in susceptible tumor cell populations may prevent tumor cell growth, migration, invasion, and angiogenesis.

Related literature

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

PMID: 17483355 DOI: 10.1158/0008-5472.CAN-06-4443

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

PMID: 21812414 DOI: 10.1021/jm2007613

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322.